Choice Institutional Equities Sees Park Medi World Reaching Rs 320 in Value

India's Most Capital-Efficient Hospital Expansion Underway

Park Medi World's subsidiary, PARKHOSP, is embarking on a significant hospital expansion project in India. The company aims to scale up its bed capacity from 3,960 beds today to 5,460 by FY28, and further increase to over 10,000 beds within the next five years. Notably, this expansion is being executed with zero equity dilution, as the entire rollout is self-funded through internal accruals.

The cluster model employed by PARKHOSP delivers a remarkable capital expenditure (capex) of INR 34 lakh per bed. This is significantly lower compared to its greenfield peers, who incur capex of INR 80-100 lakh per bed. Despite this efficiency, PARKHOSP has maintained high standards of accreditation, robotics, and ICU facilities. Furthermore, the company's upfront payment for distressed asset acquisitions ensures secured valuation, a competitive advantage that its peers cannot match.

The bed configuration of 40% general ward, 30% ICU/critical care, 20-22% twin-sharing, and the remainder as single rooms, maximizes bed density per square foot. With a de-risked pipeline and a self-sustaining cash engine, PARKHOSP's compounding trajectory remains firmly intact.

Read also: SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire

Initiating Coverage with a 'BUY' Rating

In light of this information, we initiate coverage on Park Medi World's subsidiary, PARKHOSP, with a 'BUY' rating and a target price of INR 320. This valuation is based on an Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization (EV/EBITDA) multiple of 18x in FY28E, representing an upside of 36.0% from the current price.